EcoDrugPlus

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSOGAG00000003050
Gene Symbol: PTGS1
2 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSOGAG00000002872
Gene Symbol: PTGS2
4 Cross references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSOGAG00000011622
Gene Symbol: PSMA1
4 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSOGAG00000016805
Gene Symbol: PSMA2
4 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSOGAG00000000382
Gene Symbol: PSMA3
4 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSOGAG00000010637
Gene Symbol: PSMA4
4 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSOGAG00000013560
Gene Symbol: PSMA5
4 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSOGAG00000008492
Gene Symbol: PSMA6
4 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSOGAG00000000931
Gene Symbol: PSMA7
3 Cross references
150 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOGAG00000011233
Gene Symbol: PSMA8
4 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSOGAG00000011331
Gene Symbol: PSMB1
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSOGAG00000015584
Gene Symbol: PSMB10
4 Cross references
171 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).